What type of study is this?

This is a In Vitro Study study.

What question did this study set out to answer?

To explore minimal residual disease in mantle cell lymphoma after CD19-targeted CAR T-cell therapy using a new isolation method.

December 8, 2025Blood

Live-cell pick-seq (LiP-Seq): Interrogating ultra-rare Mantle Cell Lymphoma MRD after CD19-targeted CAR T-cell therapy

View Full Paper

Ask AI

Bookmark

To explore minimal residual disease in mantle cell lymphoma after CD19-targeted CAR T-cell therapy using a new isolation method.
Developed Live-cell Pick-Seq (LiP-Seq) to isolate ultra-rare MRD cells
Collected and analyzed paired peripheral blood samples from MCL patients
Utilized next-generation sequencing and scRNA-seq analysis to assess genetic changes
68% initial complete remissions observed but only 37% progression-free survival at 3 years
LiP-Seq effectively isolated viable ultra-rare MRD cells with high-quality scRNA-seq data
Identified upregulation of IFITM2 in post-treatment MRD cells compared to pre-treatment

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

This investigation reveals upregulated minimal residual disease and impaired progression-free survival in mantle cell lymphoma using LiP-Seq after CAR T-cell therapy.

Cite This Study

Rice et al. (2025) studied this question.

synapsesocial.com/papers/69362f604fa91c937236dcb0 https://doi.org/10.1182/blood-2025-940

View Full Paper

Ask AI

Bookmark

Implication

This investigation reveals upregulated minimal residual disease and impaired progression-free survival in mantle cell lymphoma using LiP-Seq after CAR T-cell therapy.

Live-cell pick-seq (LiP-Seq): Interrogating ultra-rare Mantle Cell Lymphoma MRD after CD19-targeted CAR T-cell therapy

Key Points

Discussion

Implication

Cite This Study

Live-cell pick-seq (LiP-Seq): Interrogating ultra-rare Mantle Cell Lymphoma MRD after CD19-targeted CAR T-cell therapy

Key Points

Discussion

Implication

Cite This Study

Also Consider

Also Consider